• Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo,
with rights to commercialize Synoglide™ in the veterinary market in most countries of
the world. Allegro retains rights to human applications for its technology, enabling the
company to focus on human clinical development of its osteoarthritis candidate
• Under the terms of the agreement, Allegro has received an upfront payment and is
eligible to receive commercialization and sales milestone payments up to $35 million, in
addition to royalties on sales
• Product availability is planned for early 2026
Liege, Belgium and Shirley, NY – 25 November 2025 (08:30 CET) – Allegro NV, a biomedical
company developing transformative nanotechnology-based treatments for degenerative joint
disease, and American Regent, a leading pharmaceutical company in the U.S. specializing in
injectables for human and animal health, announced today that the two companies have
entered into an exclusive licensing deal for Allegro’s Synoglide™, a novel treatment for
osteoarthritis in the equine market.
Under the agreement, Allegro will manufacture Synoglide™ in its state-of-the art cleanroom
facility.
“The partnership with leading animal health player American Regent is a clear validation
of the potential of Allegro’s injectable hydrogel to treat osteoarthritis in the equine veterinary
market. Horses serve as a strong translational model for humans in joint disease, an exciting
prospect as we focus on human clinical development of the technology,” said Lucas Decuypere,
Chief Executive Officer at Allegro.
American Regent plans to introduce Synoglide™ for horses at the American Association of
Equine Practitioners conference in December 2025 and expects to achieve first sales in the U.S.
in early 2026. “We are eager to add this novel treatment for osteoarthritis to our veterinary
portfolio as part of our commitment to innovative solutions that improve animal health.
Synoglide™ offers a new approach to help veterinarians manage this challenging chronic
condition that affects the lives of so many animals,” said Paul Diolosa, Chief Executive Officer
at American Regent.
Synoglide™ is an intra-articular injection for horses suffering from osteoarthritis and is based on
Allegro’s proprietary nanotechnology platform, INTRICATE. This technology will be launched fo